10:30 AM EDT, 04/26/2024 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the European Medicines Agency.

The application is for intravitreal pegcetacoplan to treat geographic atrophy, a leading cause of blindness.

The company said it expects an opinion by the Committee for Medicinal Products for Human Use no later than July.

Apellis' shares were nearly 4% higher in recent trading.

Price: 49.59, Change: +1.66, Percent Change: +3.46